

Docket No. 293412US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Tiberio BRUZZESE

SERIAL NO: New US PCT Application based on PCT/EP05/00522

GAU:

FILED: Herewith

EXAMINER:

FOR: USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED N-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



\_\_\_\_\_  
Norman F. Oblon  
Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Surinder Sachar  
Registration No. 34,423

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT		ATTY DOCKET NO.	SHEET 1 OF 5 10/586863 New US PCT Application based on PCT/EP05/00522		
				293412US0PCT			
				APPLICANT	Tiberio BRUZZESE		
				FILING DATE	Herewith		
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AA		6 331 568	12/18/01	HORROBIN, David Frederick			
AB		6 384 077	05/07/02	PEET, Malcolm et al.			
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							
AL							
AM							
AN							
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AO	0 699 437	03/06/96	EP	YES	NO	
	AP	0 599 576	06/01/94	EP			NO
	AQ	0 347 056	12/20/89	EP			NO
	AR						
	AS						
	AT						
	AU						
	AV						
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
AW	MELLOR, Jan E. et al., "Omega-3 Fatty Acid Supplementation in Schizophrenic Patients", Human Psychopharmacology, Vol. 11, No.1, pgs. 39-46, 1996.						
AX	VREUGDENHIL, M et al., " Polyunsaturated fatty acids modulate sodium and calcium currents in CA 1neurons", National Academy of Science. Washington, US. Vol.93, No.22, pgs.12559-12563, 10-29-1996.						
AY	VREUGDENHIL, M et al., " Anticonvulsant properties of polyunsaturated fatty acids", Society for Neuroscience, US, Vol.22, pgs. 2106, 1996.						
AZ	VOSKUYL, Rob A., " Is marine fat anti-epileptogenic? , Nutrition and Health 2002, Vol.16, No.1, pgs. 51-53, 2002.				<input type="checkbox"/> Additional References sheet(s) attached		
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							